Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03743766 |
|
Recruitment Status :
Recruiting
First Posted : November 16, 2018
Last Update Posted : November 27, 2020
|
Sponsor:
John Kirkwood
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
John Kirkwood, University of Pittsburgh
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | December 2021 |
| Estimated Study Completion Date : | December 2021 |